The virility-restoration claim is the central marketing assertion of the Voronoff protocol and the basis for patient demand. The reported effects rest on patient self-assessment and surgeon observation without controlled comparison, blinding, or objective endocrine measurement. The claim is refuted by the immunological reality of xenograft rejection and by the absence of testosterone delivery from the implant; reported clinical effects are consistent with placebo response, postoperative attention, and selection bias in the patient population.